The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals

The Effect of Dihydralazine on Renal Tubular Function and Vasoactive Hormones in Healthy Individuals

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00311974

Enrollment

Registered

2006-04-07

Start date

2006-04-30

Completion date

2007-11-30

Last updated

2010-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Dihydralazine, Sympathetic activation, Fractional sodium excretion

Brief summary

We, the investigators at Holstebro Hospital, want to test the hypothesis that dihydralazine leads to the activation of the sympathetic nervous system in healthy individuals.

Interventions

DRUGDihydralazine

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

DOUBLE

Eligibility

Sex/Gender

MALE

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

1. Men 2. Ages 18 to 40 years. 3. Body mass index less than or equal to 30 kg/m2

Exclusion criteria

1. History or clinical signs of heart, lung, kidney, or endocrine organ disease. 2. Abnormal biochemical screening of the blood regarding: B-hemoglobin, P-sodium, P-potassium, P-creatinine, P-albumin, P-bilirubin, P-alanine aminotransferase, P-alkaline phosphatase, P-cholesterol, and B-glucose. 3. Abnormal screening of the urine regarding: albumin and glucose 4. Malignant disease. 5. Known arterial hypertension or measured 24 hour blood pressure above 135 mmHg systolic or 85 mmHg diastolic. 6. Alcohol abuse. 7. Smoking. 8. Drug use or abuse. 9. Known intolerance or allergy to dihydralazine 10. Blood donation within 1 month of the start of the study.

Design outcomes

Primary

Measure	Time frame
Fractional sodium excretion	—
Heart rate	—
Blood pressure	—

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026